The Medicines Co.’s Slimmer Cangrelor Filing Slated For April Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Company believes it has addressed all of FDA’s concerns in an April 2014 “complete response” letter relative to use during percutaneous coronary intervention, the only indication that will be the focus of a second advisory committee review.
You may also be interested in...
Cangrelor Advisory Cmte. Unsure Whether Plavix Even Needs Replacing
After a brutal panel review, The Medicines Co.’s best chance for its anti-clotting medication may be to create a “better sense of the unmet need” in the perioperative setting when Plavix use must be suspended.
Cangrelor Can’t Escape Its Past At FDA Advisory Committee
The Medicines Co.’s anti-clotting drug had one relatively positive study, but two failed ones, and that produced two lopsided “no” votes by the Cardiovascular and Renal Drugs Advisory Committee.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.